Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + DMARDs in RA (MRI Study)
NCT00996606Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2009
- Primary completion
- Apr 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Change From Baseline in Synovitis of the Wrist According to Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) Score at 4 weeks, Change From Baseline in Synovitis of the Wrist According to Relative Enhancement (RE) Before and After Contrast Injection at 4 weeks and 1 more. Started Oct 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00996606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996606.